Enliven Therapeutics, Inc. ELVN
44.75
(0.42)
(0.93%)
as of 25 Sep
- Market cap
- $3.3B
- P/E
- 0.0×
Follow ELVN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
28.66 | 19.99 | 10.28 | 8.00 | 12.86 | 14.47 | 7.29 | 4.21 | 12.38 |
Net Debt/EBITDA |
3.87 | 3.02 | 2.88 | 1.96 | 1.76 | 2.13 | 1.20 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.68 | 0.82 | 0.86 | 0.85 | 0.91 | 0.76 | 0.93 | 0.77 | 0.00 |
Capex/Depreciation |
1.53 | (0.06) | 0.03 | (2.85) | (0.05) | (0.08) | (10.00) | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (26.95%) | (32.04%) | (84.67%) | (818.29%) | (60.29%) | (276.61%) | 62.43% | 54.18% | 0.00% | |
| (25.86%) | (29.79%) | (40.31%) | (42.57%) | (55.70%) | (79.29%) | (114.45%) | (294.28%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (167,472.22%) | 0.00% | 0.00% |
Return on Tangible Assets |
(22.62%) | (29.41%) | (29.70%) | (54.64%) | (59.93%) | (58.24%) | (87.33%) | (193.04%) | 0.00% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(1.24) | (1.56) | (1.73) | (10.46) | (8.64) | (10.75) | (125.38) | (2.03) | (0.51) |
Cash per Share |
8.16 | 6.66 | 7.12 | 24.18 | 16.67 | 25.34 | 164.62 | 1.71 | 0.56 |
Shareholders Equity per Share |
8.11 | 6.58 | 6.92 | 23.34 | 15.89 | 24.25 | 164.67 | (6.09) | (0.90) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
8.11 | 6.58 | 6.92 | 23.34 | 15.89 | 24.25 | 164.67 | (6.09) | (0.90) |
Free Cash Flow |
(70.25) | (73.24) | (61.42) | (32.69) | (46.78) | (37.42) | (22.02) | (8.78) | (8.78) |
Working Capital |
458.31 | 302.21 | 240.26 | 68.04 | 85.49 | 84.16 | 26.43 | 5.87 | 9.40 |
Capital Expenditures |
0.06 | (0.04) | (0.15) | (0.61) | (0.01) | (0.02) | (0.14) | — | — |
Net Current Asset Value |
458.31 | 302.21 | 240.19 | 67.38 | 85.08 | 84.00 | 26.24 | 5.87 | 8.74 |
| Other line items | |||||||||
Quick Ratio |
27.92 | 19.70 | 9.78 | 7.78 | 12.52 | 14.12 | 6.89 | 4.03 | 11.71 |
Depreciation/Fixed assets |
1.06 | 1.62 | (5.80) | 0.24 | 1.02 | 0.63 | 0.03 | — | — |
Cash ROIC |
(7.63%) | (11.82%) | (12.42%) | (22.21%) | (26.67%) | (21.86%) | (38.60%) | 46.36% | 168.84% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.24) | (1.55) | (1.72) | (10.27) | (8.64) | (10.74) | (124.58) | (2.03) | (0.51) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.20) | 0.00 | (0.01) | (0.80) | 0.00 | 0.00 |
Average Payables |
1.75 | 0.94 | 1.99 | 2.90 | 2.17 | 1.81 | 1.28 | 0.67 | 0.67 |
Average Assets |
400.96 | 298.81 | 177.58 | 88.47 | 92.24 | 62.07 | 20.50 | 3.85 | 8.96 |
Average Common Equity |
384.72 | 277.88 | 84.54 | 4.60 | 85.23 | 17.79 | (37.58) | (20.92) | (20.92) |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates